Otros idiomas Revive Therapeutics Ltd Toronto S.E.

Acciones

RVV

CA7615161030

Diferido Toronto S.E. Otros sitios de cotización			Varia. Cinco días.	Varia. 1 de enero.
- ^CAD	-.--%		+6,67 %	-11,11 %

18/04	Revive Therapeutics Ltd. Anuncia la aceptación por la FDA de la solicitud de reunión para el producto de diagnóstico COVID largo	CI
02/04	Revive Therapeutics Ltd. Proporciona información actualizada sobre el estudio clínico con psilocibina para el trastorno por consumo de metanfetamina	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Revive Therapeutics Ltd. Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Ltd. Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27/03
Revive Therapeutics Ltd. Announces to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19/03
Revive Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	29/02
Revive Therapeutics Explores the Use of Bucillamine for Long COVID	01/02
Revive Therapeutics Ltd. Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada	16/01
Revive Therapeutics Ltd. Successfully Completes Development of A Novel Lyophilized Formulation of Bucillamine	10/01
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of A Novel Lyophilized Formulation of Bucillamine	18/12
Revive Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2023	29/11
Revive Therapeutics Ltd. Provides Update of Novel Bucillamine Formulation Development	21/11
Revive Therapeutics Ltd.?s Newly-Formed Subsidiary, Revive Diagnostics Inc. Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize Novel Long COVID Rapid Test	06/11
Revive Therapeutics Ltd. Reports Earnings Results for the Full Year Ended June 30, 2023	27/10/23
Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure	17/10/23
Revive Therapeutics Ltd. Provides Update of Novel Bucillamine Formulation Development	11/10/23
Revive Therapeutics Ltd. Announces Initiation of Novel Bucillamine Formulation Development	22/08/23
Revive Therapeutics Ltd. Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents	28/07/23
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19	06/07/23
Revive Therapeutics Ltd. Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19	30/05/23
Revive Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	30/05/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Revive Therapeutics Ltd Toronto S.E.

Acciones

RVV

CA7615161030

Otros idiomas

Filtros